SuperworthSarepta Therapeutics EPS SRPT
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$2.90
- Latest quarter, Q2 FY26
- −$0.05
- −103% on a year earlier
- Fiscal year 2025
- −$8.44
- −526% on the year before
Sarepta Therapeutics' earnings per share was −$2.90 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.05, down 103% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$8.44 | −526% |
| FY2024 | $1.98 | n/a |
| FY2023 | −$6.15 | n/a |
| FY2022 | −$8.03 | n/a |
| FY2021 | −$5.14 | n/a |
| FY2020 | −$7.06 | n/a |
| FY2019 | −$9.67 | n/a |
| FY2018 | −$5.42 | n/a |
| FY2017 | −$0.81 | n/a |
| FY2016 | −$5.46 | n/a |
| FY2015 | −$5.19 | n/a |
| FY2014 | −$3.39 | n/a |
| FY2013 | −$3.39 | n/a |
| FY2012 | −$4.96 | n/a |
| FY2011 | −$0.06 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.05 | −103% | −$2.90 | |
| Q1 FY26 | $2.88 | n/a | −$0.96 | |
| Q4 FY25 | −$3.93 | −428% | −$8.44 | |
| Q3 FY25 | −$1.80 | −629% | −$3.31 | |
| Q2 FY25 | $1.89 | +2600% | −$1.17 | |
| Q1 FY25 | −$4.60 | −1343% | −$2.99 | |
| Q4 FY24 | $1.20 | +173% | $1.98 | |
| Q3 FY24 | $0.34 | n/a | $1.22 | |
| Q2 FY24 | $0.07 | n/a | $0.42 | |
| Q1 FY24 | $0.37 | n/a | $0.08 | |
| Q4 FY23 | $0.44 | n/a | −$6.15 | |
| Q3 FY23 | −$0.46 | n/a | −$7.83 |
Against its peers
Companies in Drug Manufacturers - General nearest Sarepta Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SRPTSarepta Therapeutics | −$2.90 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| NRIXNurix Therapeutics | $2.31 | |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OGNOrganon | $0.77 | −71% a year |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Sarepta Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.